Affiliations: Department of Surgery, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan | Department of Pathology, Tri-Service General Hospital,
National Defense Medical Center, Taipei, Taiwan | Taipei Institute of Pathology, Taipei, Taiwan
Note: [] Corresponding author: Jong-Shiaw Jin, MD, PhD, Department of
Pathology, Tri-Service General Hospital, National Defense Medical Center, No.
325, Sec.2, Cheng-Gong Road, Taipei, Taiwan. Tel.: +886 2 87923311, Ext.
16736; Fax: +886 2 26913324; E-mail: jsjin@ndmctsgh.edu.tw
Abstract: Objective: Survivin and cortactin are factors that promote tumor
progression. We tested the hypothesis that survivin and cortactin expressions
correlate with the clinico-pathological parameters of colorectal
adenocarcinomas and survival time. Methods: Immunohistochemical analysis of survivin and
cortactin were performed using tissue microarrays of 119 specimens from 18
well, 50 moderately, and 27 poorly differentiated colorectal adenocarcinomas
and 24 colorectal adenomas with dysplasia. As control, 10 specimens of normal
colorectal epithelia were included. Results: The percentage of cells immunostained and the
immunostaining scores for survivin and cortactin were all significantly higher
in well-, moderately, and poorly differentiated colorectal adenocarcinomas than
in normal colorectal epithelia. The survivin immunostaining score was
significantly correlated with T, M, and AJCC/TNM stages (p < 0.05). For
cortactin, the score was significantly correlated with T and M stages (p <
0.05). Higher survivin immunostaining score was associated with higher
mortality. Conclusions: Higher expression of survivin and cortactin
correlates significantly with tumor stages and shorter survival time. Survivin
and cortactin may be good biomarkers of aggressiveness of colorectal
adenocarcinomas. Our findings require validation in independent cohorts and
these data support the potential targeting of survivin and cortactin for the
development of novel therapeutic strategies.
